Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

First Line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts)

First Line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts). Proc Am Soc Clin Oncol. 2007; 25(18S Part I of II):651s (abstr 15524).


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.